Lunsumio Approved for Relapsed or Refractory Follicular Lymphoma
Lunsumio is a first-in-class CD20xCD3 T-cell engaging bispecific antibody that targets CD20 on the surface of B cells and CD3 on the surface of T cells.
Lunsumio is a first-in-class CD20xCD3 T-cell engaging bispecific antibody that targets CD20 on the surface of B cells and CD3 on the surface of T cells.
Overall incidence of treatment-related adverse events was 91.2 percent and included lymphopenia, nausea, neutropenia
Mosunetuzumab is a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody that targets CD20 on the surface of B cells and CD3 on the surface of T cells.
The expanded approval was based on data from the phase 3 TRANSFORM and phase 2 PILOT studies.
The accelerated approval for Kymriah was based on data from the phase 2 ELARA trial.
The approval was based on data from the phase 3 ZUMA-7 trial.
The updated labeling is based on results from a safety management cohort from the ZUMA-1 study.
Parsaclisib is an investigational, highly selective, oral inhibitor of phosphatidylinositol 3-kinase delta.
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Researchers sought to determine whether lisocabtagene maraleucel would improve outcomes compared with standard of care in second-line therapy in patients with LBCL.